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Dynamics of HIV-1 Associated Kaposi Sarcoma
During HAART Therapy
Frank Nani and Mingxian Jin
Department of Mathematics and Computer Science
Fayetteville State University, Fayetteville, NC 28301, USA
Abstract –The techniques of mathematical modeling and
investigative computer simulations are used to study the
qualitative aspects of the patho-physiodynamics of HIV-1
associated Kaposi sarcoma (KS) during Highly Active
Anti-Retroviral Therapy (HAART) of AIDS. Using a system of
non-linear deterministic differential equations, the model
incorporates the biologically measurable and clinically
relevant immunological interactions and parameters. In
particular, the computer simulations elucidate the role of
CD8+ T lymphocyte in the annihilation and persistence of
Kaposi sarcoma during HAART.
Keywords: Kaposi sarcoma, mathematical modeling,
HAART efficacy, computer simulations, persistence of
Kaposi Sarcoma

1 Introduction
Human Herpes Virus 8 (HHV8) acts in association with
HIV-1 to induce lympho-proliferation and Kaposi sarcoma
(KS) in AIDS patients. The clinical and histo-pathological
aspects of KS have been documented by Kemény et al. [3],
Lesbordes et al. [5], and Zhu et al. [11].
The role of CD8+ T lymphocytes in regulating the
growth of KS has been investigated by Li et al. [6] and
Stebbing et al [8]. The use of adoptive immunotherapy with
activated autologous CD8+ T cells with interleukin-2 infusion
in treatment of AIDS was described in a paper by Klimas et al.
[4], Touloumi et al. [9], and Urassa et al. [10]. The
patho-physio-dynamics of KS during HAART has been
clinically investigated by Bihl et al. [1], and Dupont et al. [2].
In the current research, we shall present a mathematical
model of the patho-physio-dynamics of KS associated with
AIDS during HAART. This paper is extension of our earlier
mathematical model on HIV-1 AIDS dynamics during
latency phase [7]. Investigative computer simulations will be
used to elucidate the effect of adoptive transfer of CD8+ T
cells on Kaposi sarcoma dynamics during HAART. This
research is one of the major attempts to construct a clinically
plausible mathematical model which incorporates HAART
therapy, HIV-1 induced AIDS dynamics, and Kaposi
sarcoma.

2 Parameters
In this section, the model parameters, constants, and
variables are presented as modified from [7].
x1: the number density of non-HIV-1-infected CD4+ helper
T-lymphocytes per unit volume at any time t
x2: the number density of HIV-1 infected CD4+ helper
T-lymphocytes per unit volume at any time t
x3: the number density of HIV-1 virions in the blood plasma
per unit volume at any time t
x4: the number density of HIV-1 specific CD8+ cytotoxic
T-lymphocytes per unit volume at any time t
x5: the concentration of drug molecules of the HAART
treatment protocol at any time t
x6:The number of Kaposi sarcoma cancer cells in the AIDS
patient at any time t during HAART
S1: rate of supply of un-infected CD4+ T4-lymphocytes
S2: rate of supply of latently infected CD4+ T4-lymphocytes
S3: rate of supply of HIV-1 virions from macrophage,
monocytes, microglial cells and other lymphoid tissue
different from T4-lymphocytes
S4: rate of supply of CD8+ T8 lymphocytes from the thymus
D: rate of HAART drug infusion by transdermal delivery
ai, bi: constant associated with activation of lymphocytes by
cytokine interleukin-2 (IL-2) (i =1, 2, 3, 4)
αi: constant associated with HIV-1 infection of CD4+ T4
helper cells (i =1, 2, 3)

β1: the number of HIV-1 virions produced per day by
replication and budding in CD4+ T4 helper cells

β2: rate constant associated with replication and “budding” of

HIV-1 in syncytia CD4+ T4 helper cells per day per
microliter (μl) and released into the blood plasma

β3: the number of HIV-1 virions produced per day by

replication and “budding” in non-syncytia CD4+ T4 helper
cells and released into the blood plasma
ηi: constant depicting the rate of which HIV-1 virions
incapacitate the CD8+ T8 cytotoxic cells (i =1, 2)
(σ0, λ0): Michaelis-Menten metabolic rate constants
associated with HAART drug elimination
(σi, λi): Michaelis-Menten metabolic rate constants
associated with HAART drug pharmacokinetics (i =2, 3)

(σ4, λ4): Michaelis-Menten metabolic rate constants
associated with cytolytic action of CD8+ against Kaposi
Sarcoma cancer cells
γ4: constant depicting the cytolytic efficacy of CD8+ T cells
against Kaposi sarcoma cancer cells

ξi: cytotoxic coefficient where 0 ≤ ξi ≤ 1 (i = 2, 3)
qi: constant depicting competition between infected and
un-infected CD4+ T4 helper cells (i =1, 2)
ki: constant depicting degradation, loss of clonogenicity or
“death” (i =1, 2, 3, 4)
ei0: constant depicting death or degradation or removal by
apoptosis (programmed cell death) (i =1, 2, 3, 4)
Ki: constant associated with the killing rate of infected CD4+
T4 cells by CD8+ T8 cytotoxic lymphocytes (i =1, 2)
All the parameters are positive
ci: kinetic constants depicting logistic tumor growth for
Kaposi sarcoma

3 Model Equations
The following system of non-linear deterministic
ordinary
differential
equations
models
the
patho-physiological dynamics of HIV-1 induced AIDS
virions and associated Kaposi sarcoma cancer cells, CD4+
(infected and non-infected) T cells, and CD8+ T cells during
HAART therapy.
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4 Simulation results and discussion
A brief summary of the simulation results will be
presented in this section. Figure 1 and Figure 2 correspond
respectively to hypothetical HIV-1 KS patient’s physiological
parametric configurations P1 (Table 1) and P2 (Table 2).

(i) Hypothetical clinical case #1[Figure 1, P1]:
It is observed that HAART treatment successfully
annihilates the HIV-1 virions in the blood plasma and
reduces the number density of HIV-1 infected CD4+ T cells,
whereas the non-infected CD4+ T cells proliferate to
clinically efficacious levels. On the other hand, the HIV-1
specific CD8+ T cells are eliminated and consequently the
Kaposi sarcoma proliferates out of control.
(ii) Hypothetical clinical case #2 [Figure 1, P1′]:
In this scenario, the physiological parametric configuration
is the same as that of P1 except that there is an adoptive
transfer of 2000 units of ex-vivo interlenkin-2 activated
CD8+ cytotoxic T cells. In P1′, the S4 value is now assigned
to a value of 2000 instead of 10 as in P1. The therapeutic
outcome is clinically efficacious because the Kaposi
sarcoma is annihilated.
(iii) Hypothetical clinical case #3[Figure 2, P2]:
This scenario discusses the effect of HIV-1 latent viral
reservoirs on the treatment outcome. In particular, S3 is set
to a value of 1000, depicting the influx of 1000 HIV-1
virions from reservoirs such as microglial cells,
macrophages and dendritic cells. It is observed that even
though the HAART dose rate D is increased to 4000 units,
there is a subsequent therapeutic failure because the
non-infected CD4+ cell number plummets as HIV-1 virions
overwhelm the immune system. On the other hand, the
adoptive transferred 2000 units of CD8+ cells are able to
keep the Kaposi sarcoma cancer cells under the clinically
detectable level of 1000 cells.
(iv) Hypothetical clinical case #4 [Figure 2, P2′]:
The physiological parametric configuration is the same as
that of P2 except for the fact that the HAART drug dose rate
D is increased to 5000 units, and the non-infected CD4+ T
cells (x1) are given an extra boost of interleukin-2 (IL-2)
dose and as such the value of a1 is now 0.45. The outcome
is clinically efficacious because the plasma HIV-1 virions
(x3), the HIV-1 infected CD4+ T cells (x2), and the KS
cancer cells are kept under the clinically detectable level of
1000 cells, whereas the non-HIV-1 infected CD4+ T cells
(x1) repopulate to clinically efficacious level.

5 Summary
Our research can be summarized in the following
statements:
(i) It is possible for HAART therapy to annihilate the HIV
virions without necessarily eliminating KS.
(ii) Adoptive transfer of CD8+ T cells at a predetermined
dose rate can annihilate KS cancer cells.

(iii) It will require both HAART and adoptive transfer CD8+
T cells incubated with IL-2 to decimate both HIV-1

virions and the Kaposi sarcoma cancer cells.

TABLE 1. Hypothetical AIDS Patient Parametric Configuration Ρ1
S1 = 800 /day/μl
a1 = 0.15 /day/cell/μl
b1 = 0.01 /cell/μl
α1 =
0.5/day/virions/μl
k1 = 0.0005/day/μl
q1 =
0.00045/day/μl/cell
e10 =
0.0025 cells/day/μl
x10 = 500 cells/μl

1000

S2 = 800 /day/μl
a2 = 0.11 /day/cell/μl
b2 = 0.004/cell/μl
α2= 0.5/day/virions/μl
k2 = 0.005/day/μl
q2 = 0.00001/day/μl/cell
β1 = 1.5
virions/CD4+/day
K1 = 0.0001/day/μl
e20 = 0.0005 cells/day/μl
x20 = 400 cells/μl

S3 = 10 /day/μl
β2 =
0.0085virions/CD4+/day/μl
β3 = 2.75 virions/CD4+/day
α3 = 0.027 /day/virions/μl
k3 = 0.0001/day
e30 = 0.0001 /day
η1 = 0.055
ξ2 = 0.85
ξ3 = 0.0001
x30 = 1000 virions/μl
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Figure 1 Simulation results using parametric configurations Ρ1 vs. P1′
(P1′ is the modified P1: same as Ρ1 except S4 = 2000. The time axis unit is months.)
TABLE 2. Hypothetical AIDS Patient Parametric Configuration Ρ2
S1 = 800 /day/μl
a1 = 0.15 /day/cell/μl
b1 = 0.01 /cell/μl
α1 =
0.5/day/virions/μl
k1 = 0.0005/day/μl
q1 =
0.00045/day/μl/cell
e10 = 0.0025
cells/day/μl
x10 = 500 cells/μl

S2 = 800 /day/μl
a2 = 0.11 /day/cell/μl
b2 = 0.004/cell/μl
α2= 0.5/day/virions/μl
k2 = 0.005/day/μl
q2 = 0.00001/day/μl/cell
β1 = 1.5
virons/CD4+/day
K1 = 0.0001/day/μl
e20 = 0.0005 cells/day/μl
x20 = 400 cells/μl

S3 = 1000 /day/μl

β2 = 0.0085

virons/CD4+/day/μl
β3 = 2.75 virions/CD4+/day
α3 = 0.027/day/virions/μl

k3 = 0.0001/day
e30 = 0.0001 /day
η1 = 0.055
ξ2 = 0.85
ξ3 = 0.0001
x30 = 1000 virions/μl

S4 = 2000 /day/μl
a4 = 0.35
/day/cell/μl
b4 = 0.01/cell/μl
K2 = 0.0024 /day/μl
k4 = 0.08/day/μl
e40 = 0.0002
cells/day/μl
η2 = 0.055
γ4 = 0.15
x40 = 1500 cells/μl

D = 4000 units
σ0 = 0.5 mg/day
σ2 = 30 mg/day
σ3 = 5 mg/day
λ0 = 5 mg/L
λ2 = 10 mg/L
λ3 = 0.015 mg/L
x50 = 1500
cells/μl
n=5

c1 = 6.405
c2 = 0.00075
σ4 = 7 mg/day
λ4 = 5.5 mg/L
x60 =
2500cells
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Figure 2 Simulation results using parametric configurations Ρ2 vs. P2′
(P2′ is the modified P2: same as Ρ2 except a1=0.45, D=5000.The time axis unit is months.)
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